The Medical Letter on Drugs and Therapeutics
Minocycline Foam (Amzeeq) for Acne
May 4, 2020 (Issue: 1597)The FDA has approved a 4% aerosol foam formulation of minocycline (Amzeeq – Foamix) for topical treatment of inflammatory lesions of non-nodular moderate to severe acne in patients ≥9 years old. It is the first topical tetracycline...more
- Sarecycline (Seysara) – another oral tetracycline for acne. Med Lett Drugs Ther 2019; 61:43.
- AL Zaenglein et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74:945.
- Drugs for acne. Med Lett Drugs Ther 2016; 58:13.
- TM Jones et al. Pharmacokinetic comparison of once-daily topical minocycline foam 4% vs oral minocycline for moderate-to-severe acne. J Drugs Dermatol 2017; 16:1022.
- LS Gold et al. A novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol 2019; 80:168.
- TJ Raoof et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: a phase 3 study. J Am Acad Dermatol 2020; 82:832.
- LS Gold et al. Open-label extension study evaluating long-term safety and efficacy of FMX101 4% minocycline foam for moderate-to-severe acne vulgaris. J Clin Aesthet Dermatol 2019; 12:16.
- J Dosik et al. Topical minocycline foam 4%: results of four phase 1 studies evaluating the potential for phototoxicity, photoallergy, sensitization, and cumulative irritation. J Immunotoxicol 2019; 16:133.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.